Home About Us Pipeline News Investors Contacts Careers

STOCK INFORMATION

UPCOMING EVENTS

There are no scheduled events at this time. Please check back later.

FEATURED PRESS RELEASE

  • 7/16/19 1:34 pm PDT
    • Neratinib becomes the first anti-HER2 treatment to be approved in Canada, as extended adjuvant therapy for women with early stage HR-positive, HER2-positive breast cancer following adjuvant trastuzumab-based therapy.
    • Treatment with neratinib in the approved Health Canada indication resulted in a 51% reduction in the risk of invasive disease recurrence or death at 2 years versus placebo after patients completed one year of therapy following a trastuzumab-based regimen.
    • Neratinib addresses an unmet medical need, as up to 25% of HER2-positive early stage breast cancer patients treated with trastuzumab-based adjuvant treatment experience a recurrence.

     

    LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI) announced that its licensing partner Knight Therapeutics Inc. (Knight) has received marketing authorization from Health Canada to commercialize NERLYNX® (neratinib) in Canada for the extended adjuvant treatment of women with early stage hormone receptor positive, HER2-overexpressed/amplified breast cancer within one year after completion of trastuzumab-based adjuvant therapy. Health Canada approval was based on the Phasemore...

SEARCH INVESTOR RELATIONS

CONTACTS

Puma Biotechnology, Inc.
10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax

ir@pumabiotechnology.com